Efalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | CD11a |
| Clinical data | |
| Trade names | Raptiva |
| AHFS/Drugs.com | Monograph |
| Routes of administration | subcutaneous injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Melting point | 66 °C (150.8 °F) |
  (what is this?) (verify) | |
|
WikiDoc Resources for Efalizumab |
|
Articles |
|---|
|
Most recent articles on Efalizumab |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Efalizumab at Clinical Trials.gov Clinical Trials on Efalizumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Efalizumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Efalizumab Discussion groups on Efalizumab Patient Handouts on Efalizumab Directions to Hospitals Treating Efalizumab Risk calculators and risk factors for Efalizumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Efalizumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009.[1] Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.[2][3] Four cases of PML were reported in plaque psoriasis patients, an incidence of approximately one in 500 treated patients.[1]
Due to the risk of PML, the European Medicines Agency and the FDA recommended suspension from the market in the European Union and the United States, respectively.[4] In April 2009, Genentech Inc. announced a phased voluntary withdrawal of Raptiva from the U.S. market.[1][5]
References
- ↑ 1.0 1.1 1.2 PMID 19719397 (PMID 19719397)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ "Efalizumab FDA Warning". Retrieved 7 December 2008.
- ↑ PMID 20073129 (PMID 20073129)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ "EMEA press release regarding suspension" (PDF). Retrieved 20 February 2009.
- ↑ "Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market" (Press release). Genentech, Inc. 8 April 2009. Retrieved 9 April 2009.
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
- Pages with script errors
- Pages with incomplete PMID references
- Template:drugs.com link with non-standard subpage
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Infobox drug tracked parameters
- Drugs that are a monoclonal antibody
- Recombinant proteins
- Drug
- Withdrawn drugs
- Monoclonal antibody stubs